Allografts in Surgery of the Main Arteries

Status Recruiting

Clinical Trial Summary

The study will examine the results of the use of biological materials (allogeneic arterial grafts, allogeneic venous graft, autologous vein, biological bovine decellularized graft) as a bypass grafts for reconstructive interventions in patients with critical lower limb ischemia due to atherosclerotic peripheral arterial disease in the short-term and long-term postoperative periods. Histological analysis of allogeneic grafts will be carried out at various time points of graft preservation with a Roswell Park Memorial Institute 1640 cell medicum with 400mcg/ml gentamicin and 20mcg/ml fluconazole at a temperature of +4C. The physical properties of allogeneic grafts from postmortem donors (tensile and tear strength) will be evaluated at various conservation time periods (1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks). Markers of endothelial dysfunction (IL-6, endothelin-1, 6-keto-prostaglandin F1alfa, eNOS) will be evaluated in patients with critical ischemia who undergo bypass procedures with arterial and venous allografts at various time points (before surgery, 7 days, 1 month, 3 months, 6 months, 1 year after).

Clinical Trial Description

The study will include 200 patients of similar age, gender, and ethnicity, who will be divided into four groups: Group I: 50 patients who undergo arterial bypass procedures using autologous venous graft derived from great saphenous vein; Group II: 50 patients who undergo arterial bypass procedures using allogeneic venous grafts; Group III: 50 patients who undergo arterial bypass procedures using allogeneic arterial grafts; Group IV: 50 patients using biological bovine decellularized grafts. Patients will be monitored for 2 years: at inclusion, and 1, 3, 6, 12, 18, and 24 months after bypass procedures. The primary endpoint of the study will be mortality, i.e. death of the patient from any cause. Secondary endpoints of the study will be graft thrombosis and cardiovascular events such as myocardial infarction, acute coronary syndrome, transient ischemic attack, and stroke. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05455138
Study type	Interventional
Source	Ryazan State Medical University
Contact	Igor Suchkov, PhD, DMedSc
Phone	+7 (4912) 97-18-01
Email	suchkov_med@mail.ru
Status	Recruiting
Phase	N/A
Start date	December 1, 2021
Completion date	December 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04534257` - Prospective Registry to Investigate the Safety and Efficacy of the Treatment With the Selution Sirolimus Drug Coated Balloon in TASC C and D Atheroma-occlusive Infra-Inguinal Disease in Patients With Chronic Limb Threatening Ischemia From Singapore	N/A
Recruiting	`NCT02239419` - Evaluation of Carbothera in the Treatment of Foot Ulcers	N/A
Completed	`NCT01818310` - Safety and Efficacy Study of Autologous Bone Marrow Aspirate Concentrate for No-Option Critical Limb Ischemia	Phase 2/Phase 3
Completed	`NCT00941733` - Study of IN.PACT Amphirion™ Drug Eluting Balloon vs. Standard PTA for the Treatment of Below the Knee Critical Limb Ischemia	N/A
Completed	`NCT00633659` - Pilot Study of Hemospan® in Patients With Chronic Critical Limb Ischemia	Phase 2
Completed	`NCT04490408` - Surgical Bypass Versus Hybrid Approaches for Critical Limb Ischemia	N/A
Recruiting	`NCT04110327` - An All-Comers Observational Study of the MicroStent™ Peripheral Vascular Stent System in Subjects With Peripheral Arterial Disease
Recruiting	`NCT06075940` - Evaluation of the MAGNITUDE® Bioresorbable Drug-Eluting Scaffold in the Treatment of Patients With Below the Knee Disease in Australia	N/A
Completed	`NCT04058626` - TEsting for Arterial Disease in Diabetes (TrEAD) Study
Active, not recruiting	`NCT05009602` - Diagnostic Tools to Establish the Presence and Severity of Peripheral Arterial Disease in People With Diabetes
Completed	`NCT05436405` - Trans-pedal Access for Endovascular Revascularization in Complex Infra-popliteal Lesions in Critically Ischemic Limb	N/A
Completed	`NCT04107298` - Safety and Feasibility of Surmodics SUNDANCE™ Drug Coated Balloon	N/A
Active, not recruiting	`NCT06127134` - Outcomes of Straight-line Flow Versus Angiosome-targeted Angioplasty in Treatment of Critical Lower Limb Ischemia	N/A
Completed	`NCT04756115` - Impact of Nutritional and Inflammatory Status in Patients With Critical Limb-threatening Ischemia
Active, not recruiting	`NCT03970538` - PROMISE II: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia	N/A
Completed	`NCT03636867` - Laboratory, Cellular and Molecular Determinants of Clinical Success in Diabetic Patients With Critical Limb Ischemia
Active, not recruiting	`NCT01861327` - The Use of Carbon Dioxide as a Contrast Media for Performing Endovascular Procedures	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.